‘Ozempic face’; ‘GLP-1 butt’; ‘Wegovy mane’ - when the internet starts creating slang terms for a drug’s side effects it is no longer just a drug, it’s a cultural phenomenon. Now the side-effects of GLP-1 therapies for weight loss are embedded in popular culture, the opportunities for the nutricosmetics industry to help temper the impact of these side effects are compelling.
Changes in skin quality, facial volume, hair density, muscle mass and overall nutritional status are becoming increasingly visible consequences of the weight-loss journey itself 1, and these visible consequences are driving a host of new consumer needs, new commercial opportunities and, perhaps most importantly, new expectations of what support products should deliver.
However, for the nutricosmetics industry to truly take the opportunities, the established strategies and playbooks need to change and change quickly.
For more than two decades, much of the beauty-from-within category has been organized around singular ingredients linked to singular benefits. Collagen became synonymous with skin support, Biotin became closely associated with hair health, Omega-3 products carved out a position around inflammation and wellness.
However, the GLP-1 consumer does not fit comfortably within this one ingredient solving one problem framework.
Evidence increasingly suggests that the changes GLP-1 users are seeing are largely a consequence of rapid weight loss rather than direct pharmacological effects on the skin or hair. Clinical studies have shown body weight reductions of approximately 15-22% among users of leading obesity medicines, while body composition analyses indicate that approximately 25-45% of total weight lost may come from lean tissue.2 3 As calorie intake falls, nutritional intake often changes in parallel, creating additional challenges related to protein consumption and micronutrient sufficiency.4
Seen this way, changes in skin elasticity, facial volume or hair growth are not isolated aesthetic concerns, but outward manifestations of broader physiological and nutritional adaptation.
This means that someone experiencing substantial weight loss is not managing a single beauty concern, but instead is navigating interconnected changes affecting muscle mass, connective tissue, nutrient status, hydration and overall metabolic health. As a result, the industry's traditional approach of matching one ingredient to one consumer need begins to look increasingly inadequate, raising the question of how multiple physiological needs can be addressed simultaneously.
Importantly, the scientific foundations already exist for innovation in this direction. Protein adequacy during weight loss has long been recognized as essential for preserving lean tissue and maintaining physical function.5 6 Collagen peptides have accumulated a substantial evidence base, with recent systematic reviews and meta-analyses reporting improvements in skin hydration, elasticity and dermal density.7 Nutrients including iron, zinc, vitamin D and vitamin B12 are all recognized contributors to normal skin and hair physiology.8
This gives the industry a basis to build and create from, shifting away from one ingredient/ one need, repurposing existing assets and creating offerings tailored specifically for GLP-1 users.
However, industry will not be able to get away with a simple re-labeling of existing products. The GLP-1 consumer – like most healthcare consumers in the internet and AI age – is sophisticated, health literate and expecting evidence-backed claims.
This creates a higher bar for product developers, especially in a consumer who is hyper-aware of how their body is changing and reacting to using GLP-1 medications.
Not every ingredient currently promoted for hair and skin support is supported by comparable levels of evidence, while some nutrients and protein-based interventions have been extensively studied, others rely on far weaker clinical foundations.9
As a result, the category faces an important choice in rebalancing priorities between marketable ingredients and superficial differentiation and more disciplined evidence-led products and claims. The latter route may prove harder in the short term but is likely to be more sustainable as consumers become increasingly sophisticated.
Claims discipline will also be crucial as positioning a food supplement as treating hair loss caused by medication for example is not possible under most regulations around the world. A credible alternative is to link claims on the underlying physiology, where authorized wording already exists, including skin hydration, skin elasticity, normal hair growth, normal protein metabolism, maintenance of normal bones and connective tissue, while Real World Evidence (RWE) and consumer studies are useful additions to call-out user perceived benefits.
In relation to channels, the picture will fragment rather than consolidate, with pharmacy and clinical channels continuing to expect scientifically sound substantiation and precise positioning – and this will remain a key channel - however, telehealth platforms will be the natural channel for GLP-1 related products, as they already collect the variables that matter most for targeting the right support product for the right GLP-1 user, includes rate of weight loss, age, menopausal status, baseline protein intake, and history of hair loss.
Looking ahead, opportunities for the category go beyond GLP-1 alone. The late-stage pipeline of weight-loss drugs already includes dual and triple agonists and non-incretin appetite-suppressing mechanisms. We recently sized the anti-obesity medication market at more than US$30 billion at list price in 2024 and project continued growth across the decade. 10 The visible secondary effects we are discussing today such as hair loss, facial volume loss, and skin laxity are mostly downstream of rapid weight loss itself rather than of any one molecule. A category designed to tackle those issues will age better than one designed around a specific brand of medication.
In conclusion, the nutricosmetic segment has a chance to mature from a marketing proposition into a clinical-adjacent one, sitting alongside obesity care rather than imitating it. This will require evidence-led ingredient choices, science-based claims, formats that fit the physiology of an appetite-suppressed consumer, and an explicit acknowledgement that we are supporting the journey rather than treating its side effects. If we get this right, the category and the consumer benefits.
Want to learn more about how GLP-1s are reshaping the consumer health landscape visit our dedicated resource page: Unlock the GLP-1 Opportunity for Consumer Health.
References
Shape the future of consumer health.
Compelling claims to capture the minds of consumers
.svg){kind=icon}
